Dr. Gomez Zaghmout will be joined by Dr. Valentine (Trial Investigator) and Dr. Wally Carlo
Trial link: tinyurl.com/27ud5cpz @ebneo.bsky.social #neobluesky #neoEBM @mattiewolfmd.bsky.social

Our next webinar is on April 3rd, at 4:00 pm EST! Register here - uab.zoom.us/meeting/regist…
Dr. Gomez Zaghmout (Neonatal-Perinatal Fellow, University of Miami) will present the PPaX Trial, a cluster randomized trial of xylitol chewing gum in Malawi to prevent preterm birth.

Thank you.

Particularly when choosing to share it already. If you want to keep it until publication, don't submit it to the largest pediatric conference in the USA (or world?).

At that point, the only group that benefits from not sharing it further is the conference.

I'm certainly no nutrition expert so defer to you and others - but surely length is still ultimately a surrogate short term outcome?

At 2 years, or 5 years is our "primary outcome" (concern) the baby's height? Or how that growth impacted brain development (and subsequently neurodevelopment)?

If your work is meaningful, it will still be shared. Human nature. It will be "word of mouth". I think we all know how well that goes.

Sharing actual content (poster, slides) allows your views on the work to be heard more accurately.

You're already sharing your work, potentially to several hundred. They have all paid for access (and you've paid for the privilege).

Many can't because of the funds required (Hawaii is expensive!) or simply because they are doing the important work back home (patient care).

@jslaughtermd.bsky.social @mattiewolfmd.bsky.social

Validation is done within the same dataset - that's obviously important, but external validation more so especially given such wide variation in PDA practices.

Lastly - predicting an outcome doesn't mean we can change the outcome. Would want to show that acting on the score prevents surgery.

Difficult to find the enrollment period in this paper - found it by downloading the original cohort paper (2015-2016).

Is this PDA surgery, or device closure? If actually surgery, it doesn't reflect practice in most places IMO. I've not seen a surgical closure in ~6 years.

Looks like Bluesky also doesn't have an edit feature.

I'm Vienna it sounded like it maybe wasn't going to be ready by PAS. I haven't looked through the program yet.

FEED1 trial should be presented this year I think, which will hopefully provide compelling confirmatory data of this practice in a much larger trial.

Yes that's totally reasonable. Look forward to the larger cohort.

Thanks!
Multivariable analysis will be helpful in a larger cohort (how much does the GA diff account for the score diff?)

Could also include measures of prediction (AUC, Sens/Spec). Assume you used the same score cut off as in previous papers. Could a different cut off predict AKI better?

Thanks for sharing!

It says the score was calculated on DOL2 but none received PDA treatment until >7 days - is that your standard practice? Or is this excluding those who met your treatment criteria before 7 days?

Thanks for sharing! Looking forward to reading!

I often think about what society is willing to invest at the beginning of life, compared to what we invest on the aging generation. Not saying we shouldn't do both, but Pediatric/Neonatal care offers an incredible "return on investment".